Early this month, as the government trumpeted Pfizer Inc.’s record-setting health fraud settlement, the company’s general counsel, Amy Schulman, tried to put some distance between the company and the bad news.
Despite three other such settlements in eight years, “the notion that Pfizer has been convicted in previous settlements and that [the latest settlement] represents recidivism is not true,” Schulman said. “In prior instances, it was wholly unconnected to what we think of as Pfizer employees.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
